<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02267772</url>
  </required_header>
  <id_info>
    <org_study_id>HSC-MS-13-0763</org_study_id>
    <nct_id>NCT02267772</nct_id>
  </id_info>
  <brief_title>IV Acetaminophen vs IV Morphine for Pain Control in Pregnant Women</brief_title>
  <official_title>A Randomized, Controlled Trial of IV Acetaminophen Versus IV Morphine to Manage Pain in Pregnancy: Can Opioid Use be Reduced in Pregnant Women?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose: To determine if IV acetaminophen can 1) decrease pain in pregnancy women, 2)reduce&#xD;
      the amount of opioid use in pregnant women who encounter pain, 3) reduce maternal and fetal&#xD;
      adverse effects compared to opioids.&#xD;
&#xD;
      Design: This is a comparative effective trial that is a randomized, controlled trial of IV&#xD;
      acetaminophen vs. IV morphine in pregnant women.&#xD;
&#xD;
      Procedures: Women meeting inclusion/exclusion criteria will be randomized to IV acetaminophen&#xD;
      or IV morphine. The IV acetaminophen group will get up to four standard doses of IV&#xD;
      acetaminophen during their stay at the hospital. The second group will get up to six standard&#xD;
      doses of morphine. Subjects will complete a pain scale after medication administration and&#xD;
      will be asked about any side effects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale for this clinical trial The goal of analgesia in pregnancy is to reduce pain while&#xD;
      minimizing both maternal and fetal adverse effects. Current opioids used in pregnancy provide&#xD;
      minimal pain relief and are associated with adverse effects. IV acetaminophen has been shown&#xD;
      to significantly improve pain control following cesarean section and in the first stage of&#xD;
      labor. Moreover, IV acetaminophen reduces the need and consumption of opioids following&#xD;
      surgery. If IV acetaminophen can be as effective in controlling pain associated with maternal&#xD;
      medical conditions and uterine contractions with labor, then the use of parenteral opioids in&#xD;
      pregnant women and its exposure to the fetus could be reduced. This could provide new&#xD;
      opportunities in the medical management of pain in pregnancy. Thus we propose a comparative&#xD;
      effectiveness trial of IV acetaminophen compared to IV morphine.&#xD;
&#xD;
      Hypothesis:&#xD;
&#xD;
      We hypothesize that IV acetaminophen is as effective as IV morphine in reducing pain in&#xD;
      pregnant women. In doing so, IV acetaminophen can reduce the amount of narcotics needed in&#xD;
      women with pain.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
      To determine if IV acetaminophen can:&#xD;
&#xD;
        1. Decrease pain in pregnant women&#xD;
&#xD;
        2. Reduce the amount of opioid use in pregnant women who encounter pain&#xD;
&#xD;
        3. Reduce maternal and fetal adverse effects compared to opioids&#xD;
&#xD;
      Study Design:&#xD;
&#xD;
      For this comparative effective trial, we propose a randomized, controlled trial of IV&#xD;
      acetaminophen vs. IV morphine in pregnant women. Prior studies have confirmed that IV&#xD;
      acetaminophen is effective in controlling pain compared to placebo.[14,20] Thus,&#xD;
      administering just a placebo for pain control is not justified at this time.&#xD;
&#xD;
      We will include 3 different groups of pregnant populations who encounter pain for different&#xD;
      reasons.&#xD;
&#xD;
      Group 1: Pregnant women with uterine contractions, but not in labor Group 2: Pregnant women&#xD;
      with uterine contractions in the first stage of labor Group 3: Pregnant women with a medical&#xD;
      condition associated with pain.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Difficulties in recruitment&#xD;
  </why_stopped>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">April 27, 2019</completion_date>
  <primary_completion_date type="Actual">April 27, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Pain Intensity as Assessed by a Visual Analogue Scale (VAS)</measure>
    <time_frame>baseline, 120 minutes after administration</time_frame>
    <description>The visual analogue scale (VAS) ranges from 0mm to 140mm. The subject will be asked to mark with a pen on the scale to rate their pain. Negative differences in scores indicated a pain score worse than baseline and positive differences indicated an improved pain score from baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Relief Based on a 5 Point Verbal Scale</measure>
    <time_frame>24 hrs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Received Rescue Medications</measure>
    <time_frame>24 hours after administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantity of Rescue Medication Over 24 Hours</measure>
    <time_frame>24 hours after administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Amount of Study Drug Administered</measure>
    <time_frame>24 hours after administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's Global Satisfaction at 24 Hours</measure>
    <time_frame>24hrs</time_frame>
    <description>This will be patient reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Maternal Side Effects</measure>
    <time_frame>1 hour after administration</time_frame>
    <description>Maternal side effects include nausea, vomiting, headache, pruritus, insomnia, and drowsiness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Fetal Heart Rate Changes</measure>
    <time_frame>1 hour after administration</time_frame>
    <description>Changes in fetal heart rate tracing include acceleration, decelerations, and variability.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">163</enrollment>
  <condition>Pain Management in Pregnant Women</condition>
  <arm_group>
    <arm_group_label>IV Acetaminophen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV acetaminophen for pain control</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV morphine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IV morphine for pain control</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV Acetaminophen</intervention_name>
    <description>IV Acetaminophen</description>
    <arm_group_label>IV Acetaminophen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV Morphine</intervention_name>
    <description>IV Morphine</description>
    <arm_group_label>IV morphine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
        Group 1. We will include pregnant women greater than 24 weeks of pregnancy who present with&#xD;
        uterine contractions, but are not in labor and who are warranting treatment with&#xD;
        intravenous medication for pain control as part of their routine treatment. This will be&#xD;
        defined as the presence of uterine contractions documented on the tocodynamometer. However,&#xD;
        the cervix remains less than 2 cm dilated and has not changed after 1 hour after&#xD;
        re-examining her cervix.[23]&#xD;
&#xD;
        Group 2. We will include pregnant women greater than 34 weeks of pregnancy who present with&#xD;
        uterine contractions and are in the first stage of labor and who are warranting treatment&#xD;
        with intravenous medication for pain control as part of their routine treatment. This will&#xD;
        be defined as the presence of uterine contractions documented on the tocodynamometer and&#xD;
        cervical dilation greater than 2 cm, but less than 6 cm. [23]&#xD;
&#xD;
        Group 3. We will include pregnant women greater than 16 weeks of pregnancy who present with&#xD;
        pain due to a maternal medical condition including sickle cell crisis, pyelonephritis,&#xD;
        pancreatitis, cholecystitis, nephrolithiasis or headache and who are warranting treatment&#xD;
        with intravenous medication for pain control as part of their routine treatment.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        We will exclude women less than 18 years of age, less than 16 weeks gestation, with weight&#xD;
        less than 50 kg, and contraindications to acetaminophen including reported elevated liver&#xD;
        function tests, hepatic injury, hepatic disorder, active liver disease, alcoholism, chronic&#xD;
        malnutrition, known coagulopathy, hemorrhage, creatinine &gt; 1.0, or known allergy or&#xD;
        hypersensitivity to acetaminophen. We will also exclude women who have received any opioids&#xD;
        within the last 24 hours.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jerrie S Refuerzo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center, Houston</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lyndon B Johnson Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77026</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Hermann Hospital, Texas Medical Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>October 14, 2014</study_first_submitted>
  <study_first_submitted_qc>October 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2014</study_first_posted>
  <results_first_submitted>December 31, 2020</results_first_submitted>
  <results_first_submitted_qc>December 31, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 22, 2021</results_first_posted>
  <disposition_first_submitted>September 21, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>September 21, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">September 28, 2020</disposition_first_posted>
  <last_update_submitted>December 31, 2020</last_update_submitted>
  <last_update_submitted_qc>December 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Jerrie Refuerzo</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Morphine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 10, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/72/NCT02267772/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>163 were enrolled, including those in Group 1 (Pregnant women with uterine contractions, but not in labor), Group 2 (Pregnant women with uterine contractions in the first stage of labor), and Group 3 (Pregnant women with a medical condition associated with pain). The participant flow only reflects participants enrolled in Group 1 and Group 2, and not those in Group 3.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>IV Acetaminophen</title>
          <description>IV acetaminophen for pain control&#xD;
IV Acetaminophen: IV Acetaminophen</description>
        </group>
        <group group_id="P2">
          <title>IV Morphine</title>
          <description>IV morphine for pain control&#xD;
IV Morphine: IV Morphine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Randomized</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>IV Acetaminophen</title>
          <description>IV acetaminophen for pain control&#xD;
IV Acetaminophen: IV Acetaminophen</description>
        </group>
        <group group_id="B2">
          <title>IV Morphine</title>
          <description>IV morphine for pain control&#xD;
IV Morphine: IV Morphine</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="48"/>
            <count group_id="B2" value="52"/>
            <count group_id="B3" value="100"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.0" spread="5.5"/>
                    <measurement group_id="B2" value="27.5" spread="6.0"/>
                    <measurement group_id="B3" value="27.3" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="100"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Pain Intensity as Assessed by a Visual Analogue Scale (VAS)</title>
        <description>The visual analogue scale (VAS) ranges from 0mm to 140mm. The subject will be asked to mark with a pen on the scale to rate their pain. Negative differences in scores indicated a pain score worse than baseline and positive differences indicated an improved pain score from baseline.</description>
        <time_frame>baseline, 120 minutes after administration</time_frame>
        <population>For the IV Acetaminophen arm, data were collected for 24 out of 30 participants in pre-labor and 18 out of 18 participants in the 1st stage of labor. For the IV morphine arm, data were collected for 30 out of 32 participants in pre-labor and 20 out of 20 participants in the 1st stage of labor.</population>
        <group_list>
          <group group_id="O1">
            <title>IV Acetaminophen</title>
            <description>IV acetaminophen for pain control&#xD;
IV Acetaminophen: IV Acetaminophen</description>
          </group>
          <group group_id="O2">
            <title>IV Morphine</title>
            <description>IV morphine for pain control&#xD;
IV Morphine: IV Morphine</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Pain Intensity as Assessed by a Visual Analogue Scale (VAS)</title>
          <description>The visual analogue scale (VAS) ranges from 0mm to 140mm. The subject will be asked to mark with a pen on the scale to rate their pain. Negative differences in scores indicated a pain score worse than baseline and positive differences indicated an improved pain score from baseline.</description>
          <population>For the IV Acetaminophen arm, data were collected for 24 out of 30 participants in pre-labor and 18 out of 18 participants in the 1st stage of labor. For the IV morphine arm, data were collected for 30 out of 32 participants in pre-labor and 20 out of 20 participants in the 1st stage of labor.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>pre-labor group</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.67" spread="3.8"/>
                    <measurement group_id="O2" value="3.2" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>first stage of labor group</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.2" spread="13.2"/>
                    <measurement group_id="O2" value="-4.8" spread="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Relief Based on a 5 Point Verbal Scale</title>
        <time_frame>24 hrs</time_frame>
        <population>Data were not collected for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>IV Acetaminophen</title>
            <description>IV acetaminophen for pain control&#xD;
IV Acetaminophen: IV Acetaminophen</description>
          </group>
          <group group_id="O2">
            <title>IV Morphine</title>
            <description>IV morphine for pain control&#xD;
IV Morphine: IV Morphine</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Relief Based on a 5 Point Verbal Scale</title>
          <population>Data were not collected for this outcome measure.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Received Rescue Medications</title>
        <time_frame>24 hours after administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IV Acetaminophen</title>
            <description>IV acetaminophen for pain control&#xD;
IV Acetaminophen: IV Acetaminophen</description>
          </group>
          <group group_id="O2">
            <title>IV Morphine</title>
            <description>IV morphine for pain control&#xD;
IV Morphine: IV Morphine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Received Rescue Medications</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quantity of Rescue Medication Over 24 Hours</title>
        <time_frame>24 hours after administration</time_frame>
        <population>Data were not collected for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>IV Acetaminophen</title>
            <description>IV acetaminophen for pain control&#xD;
IV Acetaminophen: IV Acetaminophen</description>
          </group>
          <group group_id="O2">
            <title>IV Morphine</title>
            <description>IV morphine for pain control&#xD;
IV Morphine: IV Morphine</description>
          </group>
        </group_list>
        <measure>
          <title>Quantity of Rescue Medication Over 24 Hours</title>
          <population>Data were not collected for this outcome measure.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Amount of Study Drug Administered</title>
        <time_frame>24 hours after administration</time_frame>
        <population>For the IV Acetaminophen arm, data were collected for 30 out of 30 participants in pre-labor and 18 out of 18 participants in the 1st stage of labor. For the IV morphine arm, data were collected for 32 out of 32 participants in pre-labor and 20 out of 20 participants in the 1st stage of labor.</population>
        <group_list>
          <group group_id="O1">
            <title>IV Acetaminophen</title>
            <description>IV acetaminophen for pain control&#xD;
IV Acetaminophen: IV Acetaminophen</description>
          </group>
          <group group_id="O2">
            <title>IV Morphine</title>
            <description>IV morphine for pain control&#xD;
IV Morphine: IV Morphine</description>
          </group>
        </group_list>
        <measure>
          <title>Total Amount of Study Drug Administered</title>
          <population>For the IV Acetaminophen arm, data were collected for 30 out of 30 participants in pre-labor and 18 out of 18 participants in the 1st stage of labor. For the IV morphine arm, data were collected for 32 out of 32 participants in pre-labor and 20 out of 20 participants in the 1st stage of labor.</population>
          <units>milligrams</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>pre-labor group</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1600" spread="952.2"/>
                    <measurement group_id="O2" value="6.4" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1st stage of labor group</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1055" spread="229"/>
                    <measurement group_id="O2" value="2.3" spread="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient's Global Satisfaction at 24 Hours</title>
        <description>This will be patient reported.</description>
        <time_frame>24hrs</time_frame>
        <population>Data were not collected for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>IV Acetaminophen</title>
            <description>IV acetaminophen for pain control&#xD;
IV Acetaminophen: IV Acetaminophen</description>
          </group>
          <group group_id="O2">
            <title>IV Morphine</title>
            <description>IV morphine for pain control&#xD;
IV Morphine: IV Morphine</description>
          </group>
        </group_list>
        <measure>
          <title>Patient's Global Satisfaction at 24 Hours</title>
          <description>This will be patient reported.</description>
          <population>Data were not collected for this outcome measure.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Maternal Side Effects</title>
        <description>Maternal side effects include nausea, vomiting, headache, pruritus, insomnia, and drowsiness.</description>
        <time_frame>1 hour after administration</time_frame>
        <population>Data for this outcome measure were not collected for 5 in the IV Acetaminophen arm and 1 in the IV morphine arm.</population>
        <group_list>
          <group group_id="O1">
            <title>IV Acetaminophen</title>
            <description>IV acetaminophen for pain control&#xD;
IV Acetaminophen: IV Acetaminophen</description>
          </group>
          <group group_id="O2">
            <title>IV Morphine</title>
            <description>IV morphine for pain control&#xD;
IV Morphine: IV Morphine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Maternal Side Effects</title>
          <description>Maternal side effects include nausea, vomiting, headache, pruritus, insomnia, and drowsiness.</description>
          <population>Data for this outcome measure were not collected for 5 in the IV Acetaminophen arm and 1 in the IV morphine arm.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pruritus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>insomnia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>drowsiness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Fetal Heart Rate Changes</title>
        <description>Changes in fetal heart rate tracing include acceleration, decelerations, and variability.</description>
        <time_frame>1 hour after administration</time_frame>
        <population>Data for this outcome measure were not collected for 6 in the IV Acetaminophen arm and 4 in the IV morphine arm.</population>
        <group_list>
          <group group_id="O1">
            <title>IV Acetaminophen</title>
            <description>IV acetaminophen for pain control&#xD;
IV Acetaminophen: IV Acetaminophen</description>
          </group>
          <group group_id="O2">
            <title>IV Morphine</title>
            <description>IV morphine for pain control&#xD;
IV Morphine: IV Morphine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Fetal Heart Rate Changes</title>
          <description>Changes in fetal heart rate tracing include acceleration, decelerations, and variability.</description>
          <population>Data for this outcome measure were not collected for 6 in the IV Acetaminophen arm and 4 in the IV morphine arm.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>absence of accelerations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>late decelerations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>minimal or absent variability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 hour after administration</time_frame>
      <desc>Other (Not Including Serious) Adverse Events were not collected for 5 in the IV Acetaminophen arm and 1 in the IV morphine arm. All participants who study drug were assessed for serious adverse events (SAEs) and Mortality.</desc>
      <group_list>
        <group group_id="E1">
          <title>IV Acetaminophen</title>
          <description>IV acetaminophen for pain control&#xD;
IV Acetaminophen: IV Acetaminophen</description>
        </group>
        <group group_id="E2">
          <title>IV Morphine</title>
          <description>IV morphine for pain control&#xD;
IV Morphine: IV Morphine</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse reaction to demerol administered as rescue medication, which required narcan for reversal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="43"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="43"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="43"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Drowsiness</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="43"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jerrie S. Refuerzo, MD, Associate Professor</name_or_title>
      <organization>The University of Texas Health Science Center at Houston</organization>
      <phone>713-500-6416</phone>
      <email>jerrie.s.refuerzo@uth.tmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

